|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Roche (RHHBY), Evotec AG (EVTG.F) Sign Alzheimer's Pact Worth Up to $830 Million
9/6/2011 7:59:57 AM
Roche Holding AG (ROG) will pay Evotec AG (EVT) $10 million for the right to develop Evotec’s EVT 302 compound for Alzheimer’s disease. Evotec may receive as much as another $820 million if development and sales goals are met, as well as double-digit royalties, the Hamburg-based company said in a statement today. Basel, Switzerland-based Roche will pay for clinical development, manufacturing and commercialization, Evotec said. The compound targets monoamine oxidase type B, or MAO-B, an enzyme that breaks down dopamine in the brain and contributes to the production of free radicals, which may contribute to the spread of the disease, Evotec said.
|
|
|
|
|
|
|
|
|
|
|